Loading clinical trials...
Loading clinical trials...
A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma.
Conditions
Interventions
pazopanib
sunitinib
Locations
51
Finland
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Joensuu, Finland
Novartis Investigative Site
Lahti, Finland
Novartis Investigative Site
Seinäjoki, Finland
Novartis Investigative Site
Turku, Finland
Novartis Investigative Site
Vaasa, Finland
Start Date
May 17, 2010
Primary Completion Date
October 19, 2011
Completion Date
November 23, 2015
Last Updated
April 17, 2017
NCT07227415
NCT05127824
NCT05865730
NCT05239728
NCT04028245
NCT04338269
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions